BLong-term results of branch retinal vein occlusion: 5-year follow-up.
This study aimed to report the 5-year outcomes of patients with newly diagnosed branch retinal vein occlusion (BRVO).
A retrospective review of patient charts was conducted. Data on central macular thickness (CMT), best-corrected visual acuity (BCVA), photoreceptor integrity, number of intravitreal (IV) antivascular endothelial growth factor (anti-VEGF) injections administered, and treatment regimen were assessed.
Ninety-seven eyes from individual patients with a mean age of 70.90 ± 11.49 (38-92) were included. The mean BCVA improved, and the mean CMT decreased at all follow-up visits following treatment (p < 0.05). Thirty-two eyes (33%) gained 3 lines of BCVA at the five-year follow-up. The mean number of total IV anti-VEGF injections administered was 19 ± 13.35 (1-49) during the five-year period, and 27.83% of patients received rescue laser treatment. Fifty-four percent of eyes received three consecutive monthly loading doses of IV anti-VEGF injections. The mean change in BCVA in the loading dose (+) group was significantly greater than in the loading dose (-) group at 1-year and subsequent visits. The loading dose (+) group showed a significantly greater reduction in CMT compared to the loading dose (-) group. The mean estimated time for BCVA to decline by ≥3 lines was 117 ± 8.74 months (95% CI = 100.21-134.51).
Anti-VEGF treatment was effective in improving anatomical and functional outcomes in BRVO patients during long-term follow-up. Initial treatment with three loading doses of anti-VEGF resulted in greater vision gain and more pronounced anatomical improvement.
A retrospective review of patient charts was conducted. Data on central macular thickness (CMT), best-corrected visual acuity (BCVA), photoreceptor integrity, number of intravitreal (IV) antivascular endothelial growth factor (anti-VEGF) injections administered, and treatment regimen were assessed.
Ninety-seven eyes from individual patients with a mean age of 70.90 ± 11.49 (38-92) were included. The mean BCVA improved, and the mean CMT decreased at all follow-up visits following treatment (p < 0.05). Thirty-two eyes (33%) gained 3 lines of BCVA at the five-year follow-up. The mean number of total IV anti-VEGF injections administered was 19 ± 13.35 (1-49) during the five-year period, and 27.83% of patients received rescue laser treatment. Fifty-four percent of eyes received three consecutive monthly loading doses of IV anti-VEGF injections. The mean change in BCVA in the loading dose (+) group was significantly greater than in the loading dose (-) group at 1-year and subsequent visits. The loading dose (+) group showed a significantly greater reduction in CMT compared to the loading dose (-) group. The mean estimated time for BCVA to decline by ≥3 lines was 117 ± 8.74 months (95% CI = 100.21-134.51).
Anti-VEGF treatment was effective in improving anatomical and functional outcomes in BRVO patients during long-term follow-up. Initial treatment with three loading doses of anti-VEGF resulted in greater vision gain and more pronounced anatomical improvement.
Authors
Kiliç Müftüoğlu Kiliç Müftüoğlu, Mayer Mayer, DU DU, Feistritzer Feistritzer, Barberis Barberis, Mohan Mohan, Chhablani Chhablani
View on Pubmed